+ Watch IMUC
on My Watchlist
ImmunoCellular is the plain girl who gets hit on at the bar around closing time because she looks good next to her even uglier cousin. The company is still riding the data from a phase I trial of their personalized dendritic cell-based glioblastoma immunotherapy ICT-07, from which they reported a median PFS of seventeen months. At this year's ASCO the company reported a four-year survival of 50% from that trial. It sounds good, except that there were only 16 patients in that single-arm trial and all were enrolled by a single investigator at a single hospital. The obvious concern is that these patients were cherry-picked to be most likely to have favorable outcomes.Moving forward, the company has completed enrollment in a 278 patient placebo-controlled trial of ICT-07 and an interim safety analysis is planned for Q1 2013. The trial is expected to be complete around the end of 2013. A recently completed 19M dilutive financing severely impacted the share price but should provide sufficient cash to complete the trial.Getting back to the ugly cousin, fellow dendritic-cell based GBM vaccine developer Northwest Biotherapeutics has left no low unstooped in their grasp for dilutive cash. Their misrepresentations and outright lies, and their use of paid sockpuppets to promote them on Seeking Alpha and elsewhere, have been extensively documented in my previous underperform pitches which cannot now be linked to because CAPS is being a little bitch. So, while ImmunoCellular has extensively mined a tiny, statistically questionable phase I trial for heavy dilution over the years, they still look pretty good compared to Northwest. I expect aforementioned Seeking Alpha shills, either paid or profiteering, to renew aggressive marketing of ImmunoCellular in 2013 to manufacture a run-up into the final data.
Research in pipeline
1. microcap stock spam / endlessly pumped on Seeking Alpha2. went public in a reverse-merger to avoid SEC oversight3. Book value of 6M, while burning cash at 3M per quarter.4. reckless dilution and accounting shenanigans in the latest 10-Q filing which I read. They give stock options to outside "investor relations" firms to pump their stock.5. took them 6 years to get their lead drug candidate through phase 1 trials, which only screen for safety, not efficacy.6. Glioblastoma Multiforme affects only 2-3 in 100,000 people, so even if they win the lottery and their drug is successful, the upside is small.
It was picked by www.hechtsoft.de Trade Alerts.
Has a cancer vaccine that appears very promising.
porto. likededded it.
There are currently 2000 IMUC shares in my "fund" with break-even of around 1.42 USD. http://caps.fool.com/Blogs/fund-trades/678775.
Definitely speculative, but I figure the technology is interesting and some bright phase one clinical trial results are enough for me to take the risk
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions